BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that in 2020, biosimilar versions of erythropoietin stimulating agents (ESAs) will garner 40 percent market share for the drug class in the G7 markets (United States, France, Germany, Italy, Spain, the United Kingdom and Japan). According to new analysis from Decision Resources’ Biosimilars Advisory Service, competitive pricing and fairly aggressive uptake by U.S. nephrologists will propel biosimilar ESAs to have the second-highest market share of any of the biosimilar drug classes to be on the market. ESAs are second only to granulocyte colony-stimulating factor (G-CSF) therapies in anticipated market share in the G7 markets.
